Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07529171) titled 'HBV Reactivation in Immunocompromised Patients (REANT STUDY)' on April 4.

Study Type: Observational [Patient Registry]

Primary Sponsor: Yasar Bayindir, MD

Condition: HBV

Intervention: Drug: Antiviral

Recruitment Status: Recruiting

Date of First Enrollment: March 9, 2026

Target Sample Size: 490

Countries of Recruitment: Turkey (Turkiye)

To know more, visit https://clinicaltrials.gov/study/NCT07529171

Disclaimer: Curated by HT Syndication....